FTSE COMPANY REPORT Share price analysis relative to sector and index performance

GlaxoSmithKline GSK Pharmaceuticals and — GBP 13.83 at close 28 September 2021

Absolute Relative to FTSE UK All-Share Sector Relative to FTSE UK All-Share Index PERFORMANCE 28-Sep-2021 28-Sep-2021 28-Sep-2021

16 106 105 1D WTD MTD YTD

15.5 Absolute -0.3 -0.4 -5.4 3.1 104 100 Rel.Sector 0.6 2.7 -3.0 -7.6 15 Rel.Market 0.5 0.3 -3.7 -6.2

102 95 14.5 VALUATION 14 100 90

Trailing

13.5 98 85

Relative Price Relative Price Relative

13 PE 12.8

Absolute Price (local (local currency) AbsolutePrice 96 80 EV/EBITDA 8.7 12.5 94 75 PB 5.0 12 PCF 9.6 11.5 92 70 Div Yield 5.5 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Price/Sales 2.2 Absolute Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Relative Price 4-wk mov.avg. 13-wk mov.avg. Net Debt/Equity 1.9

100 100 90 Div Payout 69.3 90 90 80 ROE 44.2

80 80 70

Share Index) Share

Share Sector) Share - 70 - 70 60 DESCRIPTION 60 60 50 50 50 The Company is a major global healthcare group 40 RSI RSI (Absolute) 40 40 which is engaged in the creation and discovery, 30 development, manufacture and marketing of 30 30 pharmaceutical products including ,

20 20 20 over"‘the-counter (OTC) medicines and health-related RSI (Relative to FTSE UKFTSE All to RSI (Relative RSI (Relative to FTSE UKFTSE All to RSI (Relative consumer products. 10 10 10 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021

Past performance is no guarantee of future results. Please see the final page for important legal disclosures. 1 of 4 FTSE COMPANY REPORT: GlaxoSmithKline 28 September 2021

Valuation Metrics

Price to Earnings (PE) EV to EBITDA Price to Book (PB)

31-Aug-2021 31-Aug-2021 31-Aug-2021 100 12 25 ‖ ‖ 90 11 80 20 +1SD 70 +1SD 10 60 +1SD 15 Avg 50 9 Avg 40 -1SD 10 8 30 Avg 20 5 7 -1SD 10 -1SD 0 6 0 ‖ ‖ Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020

PureTech Health 120.0 Oxford Biomedica 100.0 23.8 120.0 Genus 42.5 AstraZeneca 11.5 Genus 95.7 Dechra Pharmaceuticals 40.7 Oxford Biomedica 10.8 AstraZeneca 53.3 AstraZeneca 26.6 Dechra Pharmaceuticals 8.9 Pharmaceuticals and Biotechnology 26.2 Pharmaceuticals and Biotechnology 15.0 Pharmaceuticals and Biotechnology 7.7 17.6 Hikma Pharmaceuticals 12.3 Genus 7.6 GlaxoSmithKline 12.8 Indivior 11.4 GlaxoSmithKline 5.0 Indivior -12.5 GlaxoSmithKline 8.7 Hikma Pharmaceuticals 3.8 Oxford Biomedica -120.0 PureTech Health 0.0 PureTech Health 2.1 -150 -100 -50 0 50 100 150 0 20 40 60 80 100 120 0 5 10 15 20 25 30

Price to Cash Flow (PCF) Dividend Yield % Price to Sales (PS)

31-Aug-2021 31-Aug-2021 31-Aug-2021 45 7 3.5 40 6.5 35 3 6 +1SD 30 +1SD 25 5.5 2.5 Avg +1SD Avg 20 5 -1SD 15 -1SD 2 Avg 4.5 10 5 -1SD 4 1.5 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020

Oxford Biomedica 80.0 GlaxoSmithKline 5.5 PureTech Health 15.0 Genus 56.8 Pharmaceuticals and Biotechnology 3.1 Oxford Biomedica 13.9 Dechra Pharmaceuticals 53.1 AstraZeneca 2.1 Dechra Pharmaceuticals 11.0 AstraZeneca 35.1 Hikma Pharmaceuticals 1.4 Genus 7.0 Pharmaceuticals and Biotechnology 18.8 Dechra Pharmaceuticals 0.7 AstraZeneca 6.4 Hikma Pharmaceuticals 17.5 Genus 0.5 Pharmaceuticals and Biotechnology 3.9 GlaxoSmithKline 9.6 PureTech Health 0.0 Hikma Pharmaceuticals 3.2 Indivior -9.6 Oxford Biomedica 0.0 Indivior 2.9 PureTech Health -9.9 Indivior 0.0 GlaxoSmithKline 2.2 -20 -10 0 10 20 30 40 50 60 70 80 90 0 1 2 3 4 5 6 0 2 4 6 8 10 12 14 16 Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing.

2 of 4 FTSE COMPANY REPORT: GlaxoSmithKline 28 September 2021

Valuation Metrics

Net Debt to Equity Dividend Payout (DP) Return on Equity (RoE)

31-Aug-2021 31-Aug-2021 31-Aug-2021 20 100 ‖ ‖ 50 ‖ ‖ ‖ ‖

+1SD 90 +1SD 45 15 +1SD 80 40 Avg 10 Avg 70 35 Avg -1SD 5 60 30 -1SD -1SD 0 50 25 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020 Sep-2016 Sep-2017 Sep-2018 Sep-2019 Sep-2020

Indivior 3.5 AstraZeneca 100.0 GlaxoSmithKline 44.2 GlaxoSmithKline 1.9 Dechra Pharmaceuticals 100.0 Pharmaceuticals and Biotechnology 32.7 Pharmaceuticals and Biotechnology 1.5 Pharmaceuticals and Biotechnology 79.5 AstraZeneca 23.2 AstraZeneca 1.3 GlaxoSmithKline 69.3 Hikma Pharmaceuticals 21.1 Dechra Pharmaceuticals 0.6 Genus 46.7 Genus 8.0 Hikma Pharmaceuticals 0.4 Hikma Pharmaceuticals 26.7 Dechra Pharmaceuticals 5.9 Genus 0.3 PureTech Health 0.0 PureTech Health 0.9 Oxford Biomedica 0.1 Oxford Biomedica 0.0 Oxford Biomedica -6.6 PureTech Health 0.1 Indivior 0.0 Indivior -50.0 0 0.5 1 1.5 2 2.5 3 3.5 4 0 20 40 60 80 100 120 -60 -40 -20 0 20 40 60

ROE vs. PB — sector Du Pont Analysis

30 scatter 120 60

100 50 25 ‖ ‖ INDV

80 40 20

60 30 PB 15

AZN 40 20 OXB 10 DPH GNS Pharmaceuticals 20 10

5 GSK HIK PRTC 0 0 2017 2018 2019 2020 2021 0 0 5 10 15 20 25 30 35 40 45 50 Net Margin Asset Turnover Gearing ROE (rhs) ‖ ROE Note: bar chart reflects the top and bottom five current values for the valuation ratio in question for FTSE All Shares stocks in the same sector as the stock concerned. All valuation metrics are trailing.

3 of 4 FTSE COMPANY REPORT: GlaxoSmithKline 28 September 2021

Brief description Brief description

Price to Earnings Price to Earnings (PE) is price over earnings per share. Earnings are based on the latest Gearing Gearing is Total Assets divided by Common Equity. Total Assets and Common Equity are (PE) available fiscal year earnings. each averaged over two years, that is, t and (t-1). Price to Sales (PS) Price to Sales (PS) is price divided by sales per share. It is based on sales from continuing Asset Turnover Asset turnover is Sales divided by Total Assets. Total Assets is averaged over two years, operations for the fiscal year. that is, t and (t-1). Price to Book (PB) Price to Book (PB) is price at the indicated date divided by common equity per share. Dupont Breakdown Return on Equity (RoE) = Net Margin * Gearing * Asset Turnover Common/ordinary equity is generally as reported at the most recent fiscal year-end but is Analysis adjusted to exclude minority interest, preferred stock and selected items as appropriate. RoE vs PB Plot of RoE versus PB at last month end for all FTSE UK All Share stocks in the sector Price to Cash Flow Price to Cash Flow (PCF) is price at the indicated date divided by cash flow per share. relative to the stock in question. Data may be limited to the stock in question if there are (PCF) currently no stocks in the corresponding FTSE UK All Share sector. Net Debt Equity Net Debt Equity is Net Debt as a percentage of common equity. Not calculated if Absolute Absolute graphs reflect performance for the stock in question for up to 366 days adjusted denominator (common equity) is negative for intervening corporate actions. EV to EBITDA EV to EBITDA is Enterprise Value divided by EBITDA (Earnings before Interest and Taxes, Relative Relative charts reflect the performance for the stock in question relative to the depreciation and amortisation). EV is full company Market Capitalisation at the data date corresponding sector of the FTSE All Share Index for up to 366 days, rebased to the start plus last annual net debt and Preferred Stock. Net Debt is total financial debt less cash date. Note that the stock itself may not be a FTSE All share constituent. Relative Chart and short-term investments. EBITDA is operating income plus depreciation and may be null if there are no stocks in the corresponding FTSE UK All Share sector. amortisation. RSI Relative Strength Index. Calculated as 100 minus (100 divided by (1+ratio of positive Dividend Yield % Dividend Yield reflects the dividend declared per share and/or paid for the security in versus negative time weighted returns)). Reflects 14 day average gains/losses question for the most recent fiscal year, divided by the share price. Valuation History Outlier valuation data is not shown to scale as these would distort the chart. Instead, ∥ Return on Equity Return on Equity is net income over average common equity. Not calculated if Charts denotes valuation data which falls outside display truncation limits. (RoE) denominator (average common equity) is negative Top/Bottom Reflect data for up to five top and five bottom performers for the valuation metric in Dividend Payout Total dividends divided by Net Income expressed as a percentage. Valuation Bar question. Note data may be limited to the stock in question if there are currently no Charts stocks in the corresponding FTSE UK All Share sector. Net Margin Net Margin is Net Income divided by sales.

GlaxoSmithKli ne 28 Sept ember 2021 For further information visit www.ftse.com, email [email protected] or call your local FTSE office:

Beijing +86 10 5833 2202 +44 (0) 20 7866 1810 Rio de Janeiro +55 (21) 3736 3726 Tokyo +81 (3) 3581 2811 Boston +1 888 747 FTSE (3873) Milan +39 02 3604 6953 San Francisco +1 888 747 FTSE (3873) Toronto +1 416 572 7979 Chicago +1 888 747 FTSE (3873) Mumbai +91 22 6649 4180 +1 888 747 FTSE (3873) Dubai +971 4 375 1868 New York +1 888 747 FTSE (3873) +86 21 6058 9131 Hong Kong +852 2164 3333 Paris +33 (0)1 53 76 82 89 Sydney +61 (0)2 9293 2864

© 2021 Group companies. London Stock Exchange Group companies includes FTSE International Limited (“FTSE”), Frank Russell Company (“Russell”), MTS Next Limited (“MTS”), and FTSE TMX Global Debt Capital Markets Inc (“FTSE TMX”). All rights reserved. “FTSE®”, “Russell®”, “MTS®”, “FTSE TMX®” and “FTSE Russell” and other service marks and trademarks related to the FTSE or Russell indexes are trade marks of the London Stock Exchange Group companies and are used by FTSE, MTS, FTSE TMX and Russell under licence. All information is provided for information purposes only. Every effort is made to ensure that all information given in this publication is accurate, but no responsibility or liability can be accepted by the London Stock Exchange Group companies nor its licensors for any errors or for any loss from use of this publication. Neither the London Stock Exchange Group companies nor any of their licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the results to be obtained from the use of the index/indexes referred to above or the fitness or suitability of the index/indexes for any particular purpose to which it/they might be put. The London Stock Exchange Group companies do not provide investment advice and nothing in this publication should be taken as constituting financial or investment advice. The London Stock Exchange Group companies make no representation regarding the advisability of investing in any asset. A decision to invest in any such asset should not be made in reliance on any information herein. Indexes cannot be invested in directly. Inclusion of an asset in an index is not a recommendation to buy, sell or hold that asset. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional. No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the London Stock Exchange Group companies. Distribution of the London Stock Exchange Group companies’ index values and the use of their indexes to create financial products require a licence with FTSE, FTSE TMX, MTS and/or Russell and/or its licensors. The Industry Classification Benchmark (“ICB”) is owned by FTSE. FTSE does not accept any liability to any person for any loss or damage arising out of any error or omission in the ICB. Past performance is no guarantee of future results. Charts and graphs are provided for illustrative purposes only. Index returns shown may not represent the results of the actual trading of investable assets. Certain returns shown may reflect back-tested performance. All performance presented prior to the index inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The back-test calculations are based on the same methodology that was in effect when the index was officially launched. However, back- tested data may reflect the application of the index methodology with the benefit of hindsight, and the historic calculations of an index may change from month to month based on revisions to the underlying economic data used in the calculation of the index.

4 of 4